SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWellnex Life Regulatory News (WNX)

Share Price Information for Wellnex Life (WNX)

Share Price is delayed by 15 minutes
Get Live Data
4.25    0.00 (0.00%)
Bid:
4.00
Ask:
4.50
Spread: 0.50 (12.50%)
Market Cap: £3.10m
WNX Live PriceLast checked at - London Stock Exchange

Intraday Wellnex Life Share Chart

Expanded Financing Facility

19 Sep 2025 07:00

RNS Number : 0372A
Wellnex Life Limited
19 September 2025
 

 

 

 

ASX/AIM Announcement

 

19 September 2025

 

Wellnex Life Limited (ASX/AIM:WNX)

 

Expanded Financing Facility

Wellnex Life Limited (ASX/AIM: WNX) (Wellnex Life or Company) announces that, further to the Company's announcement on 31 July 2025, the Group has entered into an additional loan facility via Reach Wholesale ("Reach") for up to A$2.5 million (the "Additional Facility"). The Additional Facility, which is secured over the assets of the Group's key subsidiaries, is for a 24-month term at an interest rate of 14% for the term of the Additional Facility. The coupon and key terms are the same terms as the loan facility via Reach announced on 31 July 2025. 

The Additional Facility will serve to ensure that the Company has the maximum flexibility available to support continued growth in the business. A$1.31 million is being drawn down immediately under the Additional Facility, which will be applied towards settlement of long-term obligations and towards general working capital. A further drawdown of A$0.365 million is expected shortly. The balance of A$0.825 million requires the prior approval of Reach in their absolute discretion.

 

To stay up to date on company news and announcements, please register your details on the Wellnex Life Limited investor portal: https://wellnexlife.investorportal.com.au/register/

This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).

For further information, please contact:

 

Wellnex Life Limited (ASX:WNX) Reach Markets

Zack Bozinovski T: 1300 805 795

Chief Executive Officer & Managing Director E: IR@reachmarkets.com.au

P: +61 3 8399 9419

E: zack.b@wellnexlife.com.au

 

UK Investors

Strand Hanson (Financial & Nominated Advisor)

James Harris / Richard Johnson Tel: +44 (0) 20 7409 3494

Orana Corporate LLP (Joint Broker) swykeham@oranacorp.com

Sebastian Wykeham

S.P. Angel Corporate Finance LLP (Joint Broker) Tel: +44 (0)20 3470 0470

David Hignell / Vadim Alexandre

 

 

 

 

About Wellnex Life

 

Wellnex Life Limited (ASX/AIM:WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing on ASX in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the Company's registered products a distribution channel with a steadily increasing global geographic footprint.

 

In December 2023, Wellnex Life acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

 

The information contained within this announcement is deemed by the Company to constitute inside information pursuant to article 7 of EU Regulation 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended.

 

To learn more, please visit: www.Wellnex Lifelife.com.au/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCZZGMLKLZGKZG
Date   Source Headline
12th Jun 20269:45 amRNSAppointment of Non-Executive Director
30th Apr 20267:30 amRNSQ3 FY26 Quarterly Update and Appendix 4C
23rd Apr 20267:00 amRNSExtension of Loan Repayment
21st Apr 20268:07 amRNSUpdate on loan repayment
7th Apr 202610:15 amRNSHolding(s) in Company
2nd Apr 20267:00 amRNSExtension of Haleon Licensing and Supply Agreement
27th Mar 20267:00 amRNSIssue of Shares
12th Mar 20267:00 amRNSBoard Changes
12th Mar 20267:00 amRNSBoard Changes
27th Feb 20267:30 amRNSHalf Yearly Report and Accounts
9th Feb 20267:00 amRNSCompany Update
29th Jan 20267:00 amRNSQ2 FY26 Quarterly Update and Appendix 4C
16th Jan 20267:00 amRNSMarket Update
15th Jan 20267:55 amRNSDirector/PDMR Shareholding
16th Dec 20257:30 amRNSTrading Update
27th Nov 20257:01 amRNSResults of AGM and Board Change
27th Nov 20257:00 amRNSWithdrawal of Resolution & Resignation of Director
27th Nov 20257:00 amRNSChair AGM Speech
10th Nov 20258:22 amRNSUpdate on Loan Repayment
3rd Nov 20257:00 amRNSUpdate on Loan Repayment
28th Oct 20257:18 amRNSNotice of Annual General Meeting
21st Oct 20257:00 amRNSResignation of CEO and Loan Repayment
20th Oct 20257:00 amRNSChairman’s letter - Shareholder Update
20th Oct 20257:00 amRNSQ1 FY26 Quarterly Report and Appendix 4C
3rd Oct 20257:12 amRNSIssue of Shares
1st Oct 20257:11 amRNSAppointment of Interim Executive Chairman
30th Sep 202510:31 amRNSAnnual Report for Year Ended 30 June 2025
22nd Sep 20257:00 amRNSCompany Update
19th Sep 20257:00 amRNSAppointment of Non-executive Chair
19th Sep 20257:00 amRNSExpanded Financing Facility
18th Sep 20257:00 amRNSAppointment of Storelink as NZ Distributor
15th Sep 20257:15 amRNSDirector Resignation
9th Sep 20257:25 amRNSAppointment of Non-Executive Chair
29th Aug 202510:12 amRNSAppendix 4E – Preliminary Final Report
15th Aug 20257:49 amRNSResignation of Joint CEO
1st Aug 20258:04 amRNSChange of Address
31st Jul 20257:33 amRNSQ4 FY25 Quarterly Report and Appendix 4C
2nd Jul 20257:13 amRNSDivestment of The Iron Company
19th May 20257:30 amRNSIssue of Shares
12th May 20252:00 pmRNSTrading Update
6th May 20257:09 amRNSBoard and Management Changes
14th Apr 20257:00 amRNSHolding(s) in Company
10th Apr 20257:00 amRNSAppointment of Powermed Plus as UK Distributor
8th Apr 20257:46 amRNSQ3 FY25 Quarterly Report and Appendix 4C
28th Mar 202510:30 amRNSHolding(s) in Company
27th Mar 20257:00 amRNSResult of WRAP Retail Offer
25th Mar 202510:30 amRNSIssue of Equity - Pain Away vendor shares
21st Mar 20257:00 amRNSAdmission to AIM and First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.